External validation of the Rotterdam Prostate Cancer Risk Calculator (RPCRC) and comparison to Stockholm3 for prostate cancer diagnosis in a Swedish population-based screening cohort

The use of the Rotterdam Prostate Cancer Risk Calculator available online to predict the risk of prostate cancer in a Swedish cohort was shown to be clinically harmful as it underpredicted the risk of clinically significant prostate cancer, while the Stockholm3 test performed well showed clinical benefits.